WO2000040752A3 - Cancer associated genes and their products - Google Patents
Cancer associated genes and their products Download PDFInfo
- Publication number
- WO2000040752A3 WO2000040752A3 PCT/GB1999/004359 GB9904359W WO0040752A3 WO 2000040752 A3 WO2000040752 A3 WO 2000040752A3 GB 9904359 W GB9904359 W GB 9904359W WO 0040752 A3 WO0040752 A3 WO 0040752A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- products
- associated genes
- cancer associated
- cancer
- genes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
The application discloses cancer-associated genes and their products, especially those identifiable by SEREX. The genes and products are used to identify, track and treat cancer such as prostate cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828840.0A GB9828840D0 (en) | 1998-12-30 | 1998-12-30 | Prostate cancer associated genes and their products |
GB9828840.0 | 1998-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000040752A2 WO2000040752A2 (en) | 2000-07-13 |
WO2000040752A3 true WO2000040752A3 (en) | 2000-11-23 |
Family
ID=10845169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/004359 WO2000040752A2 (en) | 1998-12-30 | 1999-12-22 | Cancer associated genes and their products |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9828840D0 (en) |
WO (1) | WO2000040752A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6573095B1 (en) | 1998-04-29 | 2003-06-03 | Genesis Research & Development Corporation Limited | Polynucleotides isolated from skin cells |
AU2001245693A1 (en) * | 2000-03-16 | 2001-10-03 | Northwest Biotherapeutics, Inc. | Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses |
AU2001260847A1 (en) * | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
CA2433740A1 (en) * | 2001-01-09 | 2002-07-18 | Keio University | Human glioma antigen and process for preparing the same |
US7414032B2 (en) | 2001-06-25 | 2008-08-19 | Immunofrontier, Inc. | Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL |
GB0218468D0 (en) * | 2002-08-08 | 2002-09-18 | Univ Nottingham Trent | Gastric and Colon Cancer-associated antigens |
EP1862803A1 (en) | 2006-06-02 | 2007-12-05 | Atlas Antibodies AB | Use of protein SATB2 as a marker for colorectal cancer |
EP2172477A1 (en) * | 2008-10-06 | 2010-04-07 | Atlas Antibodies AB | Epitopes derived from SATB2 and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009820A1 (en) * | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
WO1995004548A1 (en) * | 1993-08-11 | 1995-02-16 | Jenner Technologies | Prostatic cancer vaccine |
WO1997033909A2 (en) * | 1996-03-15 | 1997-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
WO1998041648A2 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
WO1999004265A2 (en) * | 1997-07-17 | 1999-01-28 | Ludwig Institute For Cancer Research | Cancer associated nucleic acids and polypeptides |
-
1998
- 1998-12-30 GB GBGB9828840.0A patent/GB9828840D0/en not_active Ceased
-
1999
- 1999-12-22 WO PCT/GB1999/004359 patent/WO2000040752A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009820A1 (en) * | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
WO1995004548A1 (en) * | 1993-08-11 | 1995-02-16 | Jenner Technologies | Prostatic cancer vaccine |
WO1997033909A2 (en) * | 1996-03-15 | 1997-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
WO1998041648A2 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
WO1999004265A2 (en) * | 1997-07-17 | 1999-01-28 | Ludwig Institute For Cancer Research | Cancer associated nucleic acids and polypeptides |
Non-Patent Citations (3)
Title |
---|
ERLICH ET AL.: "MOLECULAR CHARACTERIZATION OF TRANS-GOLGI p230", J.BIOL.CHEM., vol. 271, no. 14, 1996, pages 8328 - 8337, XP002136608 * |
FRITZLER ET AL.: "MOLECULAR CHARACTERIZATION OF GOLGIN-245, A NOVEL GOLGI COMPLEX PROTEIN CONTAINING A GRANIN SIGNATURE", J.BIOL.CHEM., vol. 270, no. 52, 1995, pages 31262 - 31268, XP002136607 * |
SAHIN U ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 25, 5 December 1995 (1995-12-05), pages 11810 - 11813, XP002129692, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
GB9828840D0 (en) | 1999-02-17 |
WO2000040752A2 (en) | 2000-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2368796A (en) | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | |
WO2000028090A3 (en) | Diagnostic assay for cancer | |
MXPA03003151A (en) | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer. | |
WO1998016507A3 (en) | New heterocyclylmethyl-substituted pyrazol derivates and their use for treating cardiovascular diseases | |
IL147017A0 (en) | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES | |
AU3499395A (en) | Ionene polymers containing biologically-active anions | |
WO2004034990A3 (en) | Methods and compositions for use in treating cancer | |
AU5047800A (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
AU4903101A (en) | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof | |
WO2004058153A9 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
WO2002030465A3 (en) | Compositions that inhibit proliferation of cancer cells | |
ZA200202822B (en) | Oncolytic combinations for the treatment of cancer. | |
AU2158601A (en) | Antiviral agent for use in treatment of cancer | |
HK1040983A1 (en) | Quinones for treatment of diseases. | |
AU4823599A (en) | Prostate cancer-associated genes | |
WO2000040752A3 (en) | Cancer associated genes and their products | |
WO2001053524A3 (en) | Cancer associated genes and their products | |
WO2000053231A3 (en) | Fatty acid-anticancer conjugates and uses thereof | |
AP2004003070A0 (en) | The method of treating cancer. | |
AU3896899A (en) | Compositions for the treatment of tumors, and uses thereof | |
ZA200002546B (en) | Sorbate-preserved compositions, method for the manufacture thereof and their use. | |
AU1991901A (en) | Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof | |
ZA200203166B (en) | Treatment of cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |